PML-RARa protein, the leukemogenic product of t (15,17) in acute promyelocytic leukemia, is cleaved into a truncated form termed DPML-RARa during all-trans retinoic acid (ATRA)-induced differentiation of NB4 cells. DPML-RARa is not formed in ATRA differentiation resistant NB4 subclones. As 2 O 3 inhibits DPMLRARa formation and differentiation-induction when given in combination with ATRA. Treatment with hexamethylene bisacetamide (HMBA) combined with ATRA enhances ATRA-induced differentiation in ATRAinsensitive NB4-CI and arsenic-resistant NB4/As cells, and is associated with stabilization of PML-RARa protein and increased DPML-RARa formation. Unlike forced expression of PML-RARa, forced DPML-RARa expression based on an estimated deletion of the Nterminal PML portion does not repress RARE-tk-luc reporter activity mediated by endogenous retinoic acid receptors. The cleavage of PML-RARa is blocked by RARa antagonist Ro-41-5253 and cycloheximide and therefore requires a RARa transactivation-dependent pathway. Proteasome inhibitor MG-132 and caspase inhibitor Z-VAD-FMK do not block ATRA-induced PML-RARa cleavage and differentiation. These data suggest that (a) ATRA treatment induces PML-RARa cleavage by induction of unknown enzymes independent of proteasome-and caspase-mediated pathways; (b) DPMLRARa might function differently from both PML-RARa and RARa; (c) failure to cleave PML-RARa and form DPML-RARa after ATRA treatment may contribute to ATRA resistance in APL cells.
Introduction
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) (de The et al., 1991; Kakizuka et al., 1991) characterized by the t(15;17) translocation that fuses the PML gene on chromosome 15 to the retinoic acid receptor a (RARa) gene on chromosome 17. The specific sensitivity of APL cells to all-trans retinoic acid (ATRA) has modified the therapeutic approach of APL resulting in 90% complete remission (CR) rates in newly diagnosed and first relapse APL patients (Huang et al., 1988; Castaigne et al., 1990; Degos et al., 1990; Warrell et al., 1991; Castaigne and Degos, 1995; Degos et al., 1995) . However, relapses usually occur within months in nearly all patients who are initially sensitive to ATRA . The relapsed patients are resistant to further ATRA treatment (Delva et al., 1993; Frankel et al., 1994; Warrell et al., 1994) . The clinical response of patients to ATRA treatment requires the presence of PML-RARa for differentiation induction Degos et al., 1995) , but the connection between PML-RARa protein levels and ATRA resistance is not clear. PML-RARa is considered to function as a dominant-negative receptor at physiologic ATRA levels and as a positive receptor at pharmacologic ATRA levels . Treatment with pharmacologic ATRA levels dissociates corepressors from PML-RARa resulting in positive signaling (Hong et al., 1997; Guidez et al., 1998; He et al., 1998; Lin et al., 1998) . In addition, there is also PML-RARa proteolysis resulting in degradation or formation of DPML-RARa, an B85 kDa cleavage product during ATRA-induced differentiation of sensitive APL cells (Koken et al., 1994; Duprez et al., 1996; Yoshida et al., 1996; Zhu et al., 1997) . ATRA-resistant NB4 cells exhibit either loss of PML-RARa protein or failure to proteolyze PML-RARa (Dermime et al., 1993; Duprez et al., 1996; Rosenauer et al., 1996; Gianni et al., 1998; Fanelli et al., 1999; Jing et al., 2001) . Complete degradation of PML-RARa during As 2 O 3 treatment decreases ATRA-differentiation sensitivity Jing et al., 2001) . Interestingly, stable transfection of PML-RARa sensitizes cell to ATRA-induced differentiation Fanelli et al., 1999) . The contribution of PML-RARa protein and ATRAinduced proteolysis to differentiation induction is poorly understood. In the present communication, we compare ATRA-induced differentiation, PML-RARa and RARa levels among several clones of NB4 cells. Our data indicate that both PML-RARa and RARa contribute to ATRA-induced differentiation and highlight the role of DPML-RARa, the ATRA-induced cleavage product of PML-RARa.
Results
Basal PML-RARa levels do not correlate with ATRA-induced differentiation in NB4 subclones PML-RARa expression and ATRA-induced differentiation were compared in several NB4 subclones. MR-2 and R4 are ATRA-resistant NB4 subclones derived after long-term culture in the presence of ATRA . NB4.306 cells is another ATRA-resistant NB4 subclone derived by X-ray mutagenesis (Dermime et al., 1993) . Western blot analysis showed that MR-2 and R4 cells express similar amounts of PML-RARa protein relative to NB4 parental cells, whereas NB4.306 cells express very little PML-RARa protein ( Figure 1a ). RARa protein is expressed at similar levels in the four clones. As shown in Figure 1b , ATRA induces differentiation in 50% NB4 cells, but not in NB4.306, MR-2 and R4 cells (o5%) as measured by NBT assay after 4 days of treatment with 1 mm ATRA. These data indicate that basal PML-RARa and RARa protein levels do not correlate with the sensitivity to ATRA-induced differentiation. PML-RARa mutation in the ligand binding domain of RARa portion has been used to explain differentiation resistance in some APL cells (Imaizumi et al., 1998; Zhou et al., 2002) . However, mutation of PML-RARa is detected in R4 cells, but not in MR-2 (Shao et al., 1997) . Thus, other mechanisms are involved in ATRA-resistance in MR-2 and NB4.306 cells.
ATRA fails to degrade PML-RARa in MR-2 cells
The effect of ATRA treatment on the fate of PMLRARa is studied in NB4 and MR-2 cells. Full-length PML-RARa decreases with appearance of a specific truncated fragment (DPML-RARa, about 85 kDa) as early as 12 h (Figure 2a) , which seems to be partially resistant to further proteolysis. The amount of DPMLRARa formed does not exactly correlate with the decrease of full-length PML-RARa, suggesting that ATRA treatment initiates both total degradation and cleavage of PML-RARa in NB4 cells. In contrast, MR-2 cells treated with ATRA, retain full-length PMLRARa with only minimal accumulation of DPML-RARa (Figure 2b ). Thus, PML-RARa proteolysis after ATRA treatment is correlated with ATRA-induced differentiation in NB4 and MR-2 cells.
Loss of PML-RARa protein contributes to differentiation resistance
Several clones including NB4.306 cells without detectable PML-RARa protein were resistant to ATRA (Dermime et al., 1993; Duprez et al., 1996) . There is an enhancement of differentiation by nonretinoid inducers in NB4-CI cells, which are insensitive to ATRA-induced differentiation . As shown in Figure 3a , 80% of the NB4-CI cells become NBT positive after ATRA plus HMBA treatment even when ATRA alone induces differentiation in o10% of the cells (Figure 3a) . Western blot analysis demonstrates a stronger PML-RARa degradation with minimal DPML-RARa formation in NB4-CI after ATRA treatment. However, ATRA in combination with HMBA attenuates PML-RARa degradation, and enhances DPML-RARa formation (Figure 3b ). In contrast to NB4-CI cells, NB4.306 cells do not respond to this combination for differentiation induction ( Figure 3c ). As shown in Figure 1a and reported by others (Dermime et al., 1993; Duprez et al., 1996) , Figure 3d ). These data suggest that both DPML-RARa formation and the level of its precursor PML-RARa are correlated with the observed differentiation synergism.
DPML-RARa is less sensitive to As 2 O 3 -mediated proteolysis in NB4 cells
Previously, we and others have reported that As 2 O 3 completely degraded PML-RARa without formation of DPML-RARa in NB4 cells Jing et al., 2001 ). We also found that As 2 O 3 partly overcame ATRA resistance in MR-2 and R4 cells and this was associated with complete degradation of PML-RARa (Jing et al., 2001) . However, As 2 O 3 decreased ATRAinduced differentiation in NB4 cells and also the amount of DPML-RARa formed (Jing et al., 2001 ). This suggests that As 2 O 3 degrades PML-RARa prior to the generation of DPML-RARa by ATRA. We performed sequential treatment by giving ATRA first followed by As 2 O 3 . As 2 O 3 did not block differentiation induction (Figure 4a ) or DPML-RARa formation in ATRA pretreated NB4 cells (Figure 4b ). These data suggest that DPML-RARa in contrast to PML-RARa is less sensitive to As 2 O 3 -mediated degradation.
As 2 O 3 resistant NB4/As cells are insensitive to ATRA-induced differentiation
We have generated NB4 clones resistant to As 2 O 3 -induced apoptosis (designated NB4/As) by continuous culture in a medium containing 1 mm As 2 O 3 . The NB4/ As pool is insensitive to ATRA-induced differentiation ( Figure 5a ). When HMBA is added together with ATRA, a synergistic differentiation is observed in NB4/As cells ( Figure 5a ). Western blot analysis demonstrates that PML-RARa protein is weakly detected immediately after As 2 O 3 removal, and HMBA increases the level of PML-RARa protein alone, and increased DPML-RARa formation is observed after adding ATRA plus HMBA ( Figure 5b ). Like NB4/As pool cells, NB4/As1 and NB4/As2 subclones cultured in the presence of As 2 O 3 have minimal levels of PML-RARa protein, decreased levels of RARa ( Figure 5c ) and are partly resistant to ATRA-induced differentiation ( Figure 5d ). However, when NB4/As1 and NB4/As2 are cultured without As 2 O 3 for 2 months, PML-RARa and RARa protein levels are restored to normal levels ( Figure 5c ), and these cells become sensitive to ATRAinduced differentiation ( Figure 5e ). These data suggest that both PML-RARa and RARa are needed for maximal ATRA-induced differentiation. As 2 O 3 -induced degradation of PML-RARa is reversible suggesting that continuous As 2 O 3 exposure is needed to maintain PMLRARa degradation.
DPML-RARa is less repressive than PML-RARa on RARE-tk-luciferase reporter activity of endogenous retinoic acid receptors
Polymerase chain reaction (PCR) technique was used to generate D*PML-RARa based on size-estimated N-terminal deletion ( Figure 6a ). The effect of D*PML-RARa on RARE-tk-luc activation after addition of ATRA was compared with that of PML-RARa and RARa. As shown in Figure 6b , the activity of RARE-tk-luc increased 2.7-and 8.1-fold after ATRA treatment at doses of 0.01 and 1 mm, respectively. As expected, forced expression of PML-RARa was repressed (475%); however, DPML-RARa expression does not significantly repress the induction of RARE-tkluc activity of endogenous retinoic acid receptors after ATRA treatment at doses of 0.01 and 1 mm. In contrast, the activity of RARE-tk-luc increased to 6.8-and 13.6-fold after ATRA treatment at doses of 0.01 and 1 mm with cotransfection of RARa. These data suggest that DPML-RARa does not inhibit the function of endogenous retinoic acid receptors, but is less potent activator of RARE-tk-luc activation than wild-type RARa.
Proteosome and caspase inhibitors do not block PML-RARa cleavage
It has been reported that PML-RARa proteolysis can be blocked by the proteosome inhibitor lactacystin and caspase inhibitor Z-VAD-FMK (Yoshida et al., 1996; Nervi et al., 1998) . The cytotoxic effect of proteasome inhibitors make it difficult to interpret the relation between PML-RARa cleavage and differentiation induction. Recently, it has been shown that a new proteasome inhibitor MG-132 was less toxic to NB4 cells (Song et al., 1999) . We pretreated NB4 cells with MG-132 for 4 h followed by treatment with different concentrations of ATRA for 4 days. At day 4, differentiation induction and PML-RARa cleavage were measured. As shown in Figure 7a , MG-132 did not inhibit PML-RARa cleavage or block ATRAinduced differentiation. However, full-length PMLRARa protein was protected from degradation by addition of MG-132. We then pretreated NB4 cells with 100 mm Z-VAD-FMK, a general caspase inhibitor. Z-VAD-FMK did not inhibit ATRA-induced differentiation, and PML-RARa cleavage was not blocked by Z-VAD-FMK (Figure 7b ). These data suggest that PML-RARa cleavage by ATRA treatment is mediated by proteosomal-and caspase-independent pathways.
ATRA induces PML-RARa cleavage by an RARa activation-mediated pathway ATRA induction of PML-RARa cleavage most likely occurs by a RARa or PML-RARa-dependent pathway.
As shown in Figure 8a , ATRA induction of PML-RARa cleavage is dose dependent and is proportional to the degree of cell differentiation. Treatment of NB4 cell with 0.001 mm ATRA does not cleave PML-RARa, and does not induce cell differentiation to a significant extent (Figure 8a ). Treatment with the RARa antagonist Ro-41-5253 blocks the effect of 0.01 mm ATRA, but not 0.1 mm ATRA (Figure 8a ). This is consistent with the requirement for excess antagonist over agonist for detectable inhibition (Apfel et al., 1992) . Treatment with CHX blocks ATRA-induced PML-RARa formation (Figure 8b ), suggesting that PML-RARa degradation requires new protein synthesis. We postulate that ATRA induces the transcription of a protease gene whose product mediates PML-RARa cleavage.
Discussion
Clinical and in vitro studies indicate that the proteolysis of PML-RARa is correlated with differentiation induction (Dyck et al., 1994; Koken et al., 1994; Duprez et al., 1996; Raelson et al., 1996; Rosenauer et al., 1996; Yoshida et al., 1996; Zhu et al., 1997; Jing et al., 2001) . PML-RARa is thought to be the leukemogenic protein in APL and its targeted removal by ATRA is thought to play an essential role during ATRA-induced APL cell differentiation. This implies that defective PML-RARa proteolysis might be one mechanism of ATRA resistance. Indeed, in several ATRA-resistant APL clones, there is failure to degrade PML-RARa Kitamura et al., 1997; Shao et al., 1997; Nason-Burchenal et al., 1998) . We have found that As 2 O 3 can degrade PML-RARa in some of these clones through an alternative pathway leading to partial recovery of ATRA-induced differentiation (Jing et al., 2001) . However, when As 2 O 3 was used to treat NB4 cells in combination with ATRA, a decreased differentiation induction was observed in vitro Jing et al., 2001 ). This suggests that some positive signaling resulting from PML-RARa protein is also removed by As 2 O 3 . It has been found that several NB4 clones without detectable PML-RARa protein were resistant to ATRA-mediated differentiation (Dermime et al., 1993; Duprez et al., 1996; Fanelli et al., 1999) . Stable transfection of PML-RARa restored the sensitivity to ATRA in one ATRA-resistant clone, NB4.007/ 6 cells . Moreover, PML-RARa stable-transfected U937 cells, a non-APL cell line, had an increased sensitivity to ATRA . These data suggest that PML-RARa indeed plays a positive signaling during ATRA action. One possible explanation is that PML-RARa functions as RARa after pharmacological ATRA dissociates corepressors from PML-RARa He et al., 1998; Lin et al., 1998 (Figure 5 ). When these cells are cultured for 1 month without As 2 O 3 , PML-RARa protein is restored to the original levels and the cells become sensitive to ATRA-induced differentiation (Figure 5c ). These results indicate that PML-RARa contributes to ATRA-induced differentiation in NB4 cells even though it is proteolysized by ATRA treatment. If PML-RARa is degraded completely as after As 2 O 3 treatment, it cannot respond to ATRA treatment. We and other groups have found that ATRA and As 2 O 3 proteolized PML-RARa differently (Jing et al., 2001; Zhu et al., 2001) . Thus, ATRA, unlike As 2 O 3 , leads to a decrease in full-length PML-RARa with formation of a specific 85 kDa fragment product, termed DPML-RARa in NB4 cells (Figure 2a ) Gianni et al., 1998; Fanelli et al., 1999; Idres et al., 2001; Jing et al., 2001; Jing et al., 2002) . DPML-RARa appears to delete the N-terminal portion of PML, since the RARa antibody used is against the C-terminal RARa region. Based on its apparent size (85 kDa), DPML-RARa is likely to lack the RING finger and B-Boxes of the PML moiety of PML-RARa. PML-RARa degradation by As 2 O 3 treatment requires a specific sumolation site in K160 of the PML N-terminal portion Lallemand-Breitenbach et al., 2001) . Data in Figure 4 and another report (Gianni et al., 1998) show that DPMLRARa is resistant to As 2 O 3 -mediated degradation. The DPML-RARa formed is not degraded, and the ATRAinduced differentiation is not inhibited when As 2 O 3 is given after ATRA treatment (Figure 4) . The enhancement by HMBA of ATRA-induced differentiation in NB4-CI and NB4/As cells is correlated with increased levels of PML-RARa and DPML-RARa (Figures 3 and 5) . Moreover, it has been found that full-length PML-RARa and PML-RARa with deleted N-terminal portion (DC/R, similar to our D*PML-RARa) have an equal ability to increase ATRA-induced differentiation at 1 mm after stable transfection into U937 cells (Grignani et al., 1999) . Interestingly, we observed that DPML-RARa is formed in U937 cells stably transfected with full-length PMLRARa after 1 mm ATRA treatment (data not shown). ATRA levels (10 À9 mm) that fail to cleave PML-RARa into DPML-RARa (Figure 8a ) do not induce differentiation, supporting the notion that PML-RARa cleavage may be important for differentiation induction.
Failure to cleave PML-RARa may be one of the mechanisms of ATRA resistance in APL cells. Thus, it is worthwhile to identify how PML-RARa is cleaved after ATRA treatment. Our present data suggest that newly synthesized proteins through RARa and/or PML-RARa transactivation are involved in the ATRA-induced PML-RARa cleavage (Figure 8) . It has been shown that ATRA-induced PML-RARa proteolysis occurs through proteasome-mediated pathways (Yoshida et al., 1996; Zhu et al., 2001) . DNA microarray analysis revealed that ubiquitin-activating enzyme E1-like (UBE1L) is induced in NB4 cells after ATRA treatment. PML-RARa cotransfection with UBE1L led to PMLRARa degradation (Kitareewan et al., 2002) . These data suggest that ATRA-induced UBE1L might mediate the observed PML-RARa cleavage. Our data indicate that ATRA induces PML-RARa proteolysis through at least two pathways, complete degradation and cleavage. The proteasome inhibitor MG-132 blocks PML-RARa degradation, but not cleavage (Figure 7a ). These data suggest that ATRA-induced UBE1L expression may mediate PML-RARa degradation, but not cleavage. Caspase inhibitors have been reported to block ATRA-induced PML-RARa degradation, and a caspase 3 cleavage site is found in the PML moiety near the . However, based on the estimated molecular weight of DPMLRARa, this site is far from the predicted cleavage site. Morever, we find that caspase inhibitor Z-VAD-FMK does not block DPML-RARa formation (Figure 7b ). These data suggest that ATRA-induced PML-RARa cleavage may occur through a novel pathway. Identifying the enzymes that cleave PML-RARa will help us understand the mechanisms of ATRA-resistance and how to overcome them.
Materials and methods

Reagents
ATRA was purchased from Sigma Chemical Co. (St Louis, MO, USA). As 2 O 3 (0.1%) was provided by Dr Ting-Tong Zhang (Harbin, China). MG-132 and Z-VAD-FMK were obtained from Calbiochem (San Diego, CA, USA). Anti-RARa (F region) RPa(F) was kindly provided by Dr P Chambon (France).
Cell lines
NB4 t(15;17) (obtained from M Lanotte (Lanotte et al., 1991) ) and its resistant subclones MR-2, R4 (obtained from Dr W Miller Jr) and NB4.306 (obtained from Dr Gambacorti) (Dermime et al., 1993) are cultured in RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, 1 mm l-glutamine and 10% fetal bovine serum. NB4/As cells are established by culturing NB4 cells in the presence of As 2 O 3 gradually from 0.1 to 1 mm over 6 months. The stable clones, which grow in the presence of 1 mm As 2 O 3 , are selected. NB4-CI cells are insensitive but not resistant to ATRA-induced differentiation as previously reported . Cells in logarithmic growth are seeded at 1 Â 10 5 cells/ml for studies and are done in duplicate and repeated at least three times. NBT reduction is done as previously reported.
Western blot analysis
Protein extracts (50 mg) prepared with RIPA lysis buffer (50 mm Tris-HCl, 150 mm NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mm PMSF, 100 mm leupeptin and 2 mg/ml aprotinin, pH 8.0) are separated on an 8% SDSpolyacrylamide gel, and transferred to nitrocellulose membranes. The membranes are stained with 0.2% Ponceau S red to assure equal protein loading and transfer. After blocking with 5% nonfat milk, the membranes are incubated with antiRARa antibody. The immunocomplex is visualized by chemiluminescence (Jing et al., 2001) .
Plasmid construction
The PML-RARa expression plasmid pSG5/PML-RARa (provided by Dr Z Chen) is used to construct PML-RARa deletion mutant. Deletion mutant D*PML-RARa is constructed by PCR amplification of pSG5/PML-RARa template using the following primers: sense primer, 5 0 -AAGGATCCACCATGGTGCGTGAGTTCCTGGA-3 0 ; anti- 0 based on the method reported by Le et al. (1996) , who generated PML mutation. The sense primer is the same as MU3 in their studies. Antisense primer is designed from RARa portion in antisense orientation. The perfect Kozak sequence (Kozak, 1986 ) is incorporated into the sense primer to generate the translation initiation site. PCR amplifications are carried out by Klen Taq 1 and Pfu polymerases in a 15 : 1 ratio as described by Barnes (1994) to minimize the possibility of mutation. The cDNA is digested with the restriction endonuclease BamHI and inserted into a pSG5 vector (Stratagene) at the BglII site. The correct orientation of the inserted cDNA is verified by brief restriction mapping DNA sequencing.
Cell culture and transient expression analysis
Transient transfections using 293T cells, maintained in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum (FCS), are performed using lipofectimine transfection reagent (Gibco) . Cells are transfected with 0.5 mg RARE-tk-luciferase reporter alone or with 1 mg of PML-RARa, DPML-RARa or RARa per well in 12-well plate. A measure of 40 ng/well of Renilla luciferase is used as an internal control for transfection efficiency. Cells are treated with either ATRA at 1 Â 10 6 mol/l or ATRA 1 Â 10 8 mol/l for 48 h after 24 h transfection. Luciferase activities are performed using commercial Dual-Luciferase Reporter Assay System, according to the supplier's recommendation (Promega). All transfections were performed at least three times. 
